How much revenue does U.s. Stem Cell make?

U.s. Stem Cell reported $82,049 in revenue for fiscal year 2022, down 59.1% from $200,749 in fiscal year 2021.

What is U.s. Stem Cell's largest business segment?

Product, with $66,540 or 81% of segment revenue in fiscal year 2022. Next: Service (19%).

What companies are similar to U.s. Stem Cell?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include South American Gold Corp. (SAGD), Pathfinder Cell Therapy, Inc. (PFND), Xeno Transplants Corporation (XENO), Amarantus BioScience Holdings, Inc. (AMBS).

U.s. Stem Cell, Inc. (USRM) Stock

About U.s. Stem Cell, Inc.

U.S. Stem Cell, Inc. engages in the research, development, and commercialization of stem cell and regenerative treatments in the United States and internationally. The company develops MyoCell, an autologous muscle stem cell therapy which is preparing for phase II/III clinical trials for the treatment of heart damage in heart failure patients; MyoCell SDF-1, an autologous cell therapy which comple...

At a glance

U.s. Stem Cell reported revenue of $82,049 for fiscal year 2022, down 59.1% from fiscal year 2021, and net income of -$2.86 million. Its largest business segment, Product, brought in 81% of segment revenue in fiscal year 2022.

Figures from company filings; latest fiscal year ended December 31, 2022.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.